What Oflomac-M Forte Treats: Main Uses and Benefits

Oflomac-M Forte is commonly used to provide supportive relief in clinical settings marked by heightened patient distress and intense manifestations. It is a fixed-dose combination (FDC) therapy applied across domains where additional symptomatic support is needed. The FDC category is relevant in contexts involving heightened systemic burden and is often used to help manage symptoms associated with acute or episodic changes.

Supportive Relief in Acute Symptomatic Episodes

This medication is considered relevant in situations involving symptoms related to physical discomfort where symptoms appear suddenly or intensify over time. It is commonly used to help with managing certain distressing symptoms, offering supportive therapeutic benefit that may help make acute episodes easier to tolerate and manage. Common applications involve conditions presenting with systemic or localized discomfort and disruptive symptom manifestations.

“Its use may assist with providing improved comfort during phases of heightened symptoms.”

Managing Challenging Symptom Intensity

Oflomac-M Forte helps address symptom clusters that create noticeable interference with daily stability or functional comfort. It is applied in addressing pronounced manifestations that become difficult to tolerate. Its use may assist with providing supportive relief when symptoms interfere with routine activities. This supportive approach supports general well-being during symptomatic phases by helping to ease the overall symptom load.

---

Quick Fact: Supports management of Symptoms that interfere with daily functioning

Regulatory References

1. CDSCO (India's Regulator) Guidelines for Fixed-Dose Combinations

Oflomac-M Forte is a fixed-dose combination medicine whose use is strictly governed by the regulatory restrictions of its active ingredients, Ofloxacin and Metronidazole. Eligibility is generally restricted to adults who do not possess any of the official contraindications.

Who Must Not Use Oflomac-M Forte (Absolute Contraindications)

The medicine is prohibited for the following populations, as stated in official product labeling:

• Age Restriction: It is contraindicated in children and adolescents under 18 years of age due to the officially documented risk of irreversible arthropathy (cartilage damage) associated with the Ofloxacin component.
• Hypersensitivity: Patients with known hypersensitivity to Ofloxacin, Metronidazole, or any other medicine in the Fluoroquinolone or Nitroimidazole classes must not use this combination.
• Reproductive Status: Use is contraindicated during both pregnancy and lactation.
• Specific Conditions: Individuals with a history of epilepsy, previous tendon disorders linked to Fluoroquinolone use, or conditions such as Cockayne syndrome are prohibited from using this medicine.

Populations Requiring Conditional Use

Use of Oflomac-M Forte may be restricted and requires careful monitoring in:

• Older Adults: Geriatric patients have an officially recognized increased risk for serious adverse reactions, notably tendon rupture.
• Organ Function: Patients with impaired renal function or severe hepatic impairment are eligible only under specific conditions.
• Neurological Concerns: Caution is warranted for individuals with pre-existing CNS disorders or Myasthenia Gravis.

Oflomac-M Forte's interaction profile is strictly defined by regulatory authorities based on the combined effects of its active ingredients, Ofloxacin and Metronidazole.

Formal Contraindications and Restrictions

Co-administration with Disulfiram is formally contraindicated due to the risk of psychotic reaction. Consumption of alcohol or products containing propylene glycol is also contraindicated during treatment and for at least three days after the last dose, owing to the potential for a disulfiram-like reaction.

Drug and Substance Interactions

The systemic exposure of Ofloxacin is substantially reduced by co-administration with products containing metal cations, such as antacids, Sucralfate, or iron salts. The regulatory label mandates a two-hour time separation before or after Ofloxacin administration to avoid this pharmacokinetic interference. Both Ofloxacin and Metronidazole can potentiate the anticoagulant effect of Warfarin and other oral anticoagulants, leading to an officially documented increased bleeding risk. The combination is also associated with a heightened risk of additive toxic effects with specific drug classes; for example, co-administration with drugs that prolong the QTc interval or with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is officially noted to increase the risk of QTc prolongation or CNS stimulation, respectively. Furthermore, co-administration with Busulfan is associated with increased Busulfan serum concentrations.

Population-Specific Considerations

Regulatory documentation notes reduced clearance of Metronidazole in patients with severe hepatic impairment and reduced Ofloxacin clearance in those with impaired renal function, which can lead to increased systemic exposure.

How Oflomac-M Forte Works

Oflomac-M Forte is a fixed-dose combination that exerts its effects through two distinct pharmacodynamic mechanisms targeting bacterial and protozoan cells. The first component, Ofloxacin, is a fluoroquinolone that acts by interfering with essential enzymes within the bacterial cell nucleus.

Fluoroquinolone-Mediated DNA Gyrase Inhibition

Ofloxacin enters the bacterial cell and targets DNA gyrase (topoisomerase II) and topoisomerase IV. These enzyme targets are critical for managing the topology of bacterial DNA, including supercoiling, unwinding, and separation during replication and transcription. By inhibiting the action of these enzymes, Ofloxacin modifies early molecular steps, interrupting the DNA replication cascade. This pathway disruption prevents proper DNA processing and separation, which culminates in bacterial cell death.

Nitroimidazole-Induced DNA Strand Breakage

The second component, Metronidazole, operates primarily in anaerobic organisms and protozoan parasites. Metronidazole is a prodrug that undergoes reductive activation within the susceptible cell, a process facilitated by electron transport proteins. This activation initiates a molecular cascade, yielding highly reactive cytotoxic intermediates and free radicals. These intermediates cause direct chemical damage to the pathogen's DNA, resulting in the loss of its helical structure and eventual strand breakage. This process alters the electron transport and nucleic acid synthesis within the cell, leading to reduced pathogen viability.

How to Use Oflomac-M Forte

This section outlines the standardized usage principles for Oflomac-M Forte, a Fixed-Dose Combination (FDC) medicine, derived from the standardized guidelines governing its active components, Ofloxacin and Metronidazole. The focus is strictly on administration rules and dosing patterns.

---

Administration Scope

Category	Principle of Use
Route of Administration	The medicine is approved for Oral administration only.
Dosing Schedule & Frequency	The FDC unit is typically administered on a Twice Daily (BID) schedule, with doses spaced approximately 12 hours apart to ensure systemic exposure. The prescribed course is fixed and short-term, generally ranging from 7 to 14 days.
Timing in Relation to Meals	Oflomac-M Forte may be taken with or without food. Taking it with food may help mitigate any potential gastrointestinal discomfort.
Preparation and Intake	The oral tablets must be swallowed whole and should not be crushed, broken, or chewed. Liquid formulations, where available, require proper shaking before use and accurate measurement.

---

Procedural Constraints and Adjustments

Compliance with the full fixed duration of the course is required, even if symptoms subside rapidly.

For proper absorption, the intake of Oflomac-M Forte must be separated by at least two hours from any products containing polyvalent cations, such as antacids or supplements containing iron, magnesium, or zinc.

Dosage adjustments are essential for the Metronidazole component in patients with severe hepatic impairment (Child-Pugh C), typically requiring a reduction of approximately 50%. If a dose is missed, the patient should take it as soon as remembered unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped. Doubling the dose is prohibited.

Research Evidence / Overview of Studies

Phase 3 Trials: Evaluation in Mixed Infections

Research has explored whether the combination treatment, consisting of ofloxacin (a fluoroquinolone antibiotic) and metronidazole (an antiprotozoal and antibacterial agent), is associated with a change in symptoms across various mixed bacterial and parasitic infections, such as certain forms of diarrhea and dysentery. The studies examined whether this combined action, which targets both aerobic and anaerobic microorganisms, was associated with a reduction in symptom severity.

Studies on Symptom Resolution

Clinical trials have evaluated the effect of this combination therapy, particularly in gastrointestinal infections. One comparative study examined the combination in managing conditions like Pelvic Inflammatory Disease (PID), noting its role as an option alongside other regimens. Outcomes from various studies indicate that:

• Participants receiving the combination treatment typically show initial improvement in symptoms within three to five days of starting the course.
• Observed rates of clinical resolution in certain infections have been reported to be over 90% upon follow-up after the full treatment course.

Long-Term Safety and Tolerability

Safety studies have monitored the profile of the two components. The most frequently reported adverse events across trials included nausea, vomiting, metallic taste, headache, and dizziness. These events were generally reported as transient and mild to moderate in severity.

• Discontinuation rates due to adverse events were typically low across most completed studies.
• The trials included a small number of participants with liver or kidney impairment, and the potential for increased risk in these populations has been a point of review across safety monitoring efforts.

Population Health Impact

Meta-analyses and public health data have investigated the role of this dual therapy in managing widespread infectious diarrhea and dysentery. For instance, one analysis compared rates of emergency department visits between treatment and control populations and noted a potentially lower rate in the treatment population over a one-year period, suggesting an impact on infection recurrence or severity.

Common questions about Oflomac-M Forte (FAQ)

---

Q: What is Oflomac-M Forte used for?

A: Oflomac-M Forte is a prescription combination medication that contains Ofloxacin and Metronidazole. It is indicated for use in managing infections caused by certain types of bacteria and parasites, such as those that may be involved in diarrhea and dysentery.

---

Q: What are the main ingredients in Oflomac-M Forte?

A: The two active ingredients in this medication are:

• Ofloxacin, which belongs to a class of antibiotics known as fluoroquinolones.
• Metronidazole, which is an antibiotic effective against certain bacteria and parasites.

---

Q: What are the common side effects that may occur with Oflomac-M Forte?

A: As with many medications, Oflomac-M Forte is associated with potential side effects. The most commonly reported side effects may include:

• Nausea and/or vomiting
• Headache
• Dizziness or lightheadedness
• A metallic taste in the mouth
• Loss of appetite

Contact a healthcare provider if any side effects are severe or persistent.

---

Q: Can Oflomac-M Forte be taken by people who are pregnant or breastfeeding?

A: Current information suggests that Oflomac-M Forte is generally not recommended for use by individuals who are pregnant or breastfeeding. If you are pregnant, planning to become pregnant, or breastfeeding, you should discuss this with your doctor before using the medication. The decision to prescribe this medicine depends on a careful assessment of potential benefits versus risks by a healthcare professional.

---

Q: Are there any warnings related to driving or operating machinery while taking this medication?

A: Yes. Oflomac-M Forte may cause side effects such as dizziness or drowsiness in some people. Due to this potential effect, it is generally recommended to use caution when performing activities that require mental alertness, such as driving or operating heavy machinery, until you are aware of how the medicine affects you.

---

Q: Is it safe to consume alcohol while taking Oflomac-M Forte?

A: It is generally advised to avoid consuming alcohol during treatment with Oflomac-M Forte and for at least 48 hours after the last dose. Combining this medicine with alcohol may lead to unpleasant reactions such as flushing, headache, nausea, and vomiting.

How to Store and Dispose of Oflomac-M Forte?

The storage and disposal of Oflomac-M Forte must strictly adhere to regulatory labeling to maintain its stability and prevent misuse.

Storage Requirements

The medicine should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must not exceed 30 C (86 F). The product must be protected from light and moisture and should be kept in a tight, light-resistant container. As a mandatory safety requirement, always keep Oflomac-M Forte out of the reach of children and pets.

Disposal Instructions

Do not flush unused or expired medicine down the toilet or pour it down the drain. Official guidelines recommend using a drug take-back program. If a take-back option is unavailable, remove the medicine from its original container, mix it with an undesirable substance (like dirt or used coffee grounds), place the mixture in a sealed bag or container, and discard it in the household trash. Do not use the product past the labeled expiry date.